High mRNA Expression of

Biomarkers, Tumor / genetics Carcinoma, Hepatocellular / genetics Case-Control Studies Cell Cycle Proteins / genetics Chromosomal Proteins, Non-Histone / genetics Female Follow-Up Studies Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Liver Neoplasms / genetics Lymphocytes, Tumor-Infiltrating / immunology Male Neoplasm Recurrence, Local / genetics Prognosis RNA, Messenger / genetics Survival Rate Tumor Microenvironment

Journal

Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127

Informations de publication

Date de publication:
2021
Historique:
received: 27 03 2021
revised: 30 06 2021
accepted: 31 07 2021
entrez: 30 8 2021
pubmed: 31 8 2021
medline: 18 1 2022
Statut: epublish

Résumé

Centromere proteins (CENPs) are the main constituent proteins of kinetochore, which are essential for cell division. In recent years, several studies have revealed that several CENPs were aberrantly expressed in hepatocellular carcinoma (HCC). However, numerous centromere proteins have not been studied in HCC. In this study, we used databases of Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), the Kaplan-Meier Plotter, cBioPortal, the Human Protein Atlas (HPA), and TIMER (Tumor Immune Estimation Resource) and immunohistochemical staining of clinical specimens to investigate the expression of 15 major centromere proteins in HCC to evaluate their potential prognostic value. We found that the mRNA levels of 4 out of 15 centromere proteins (CENPL, CENPQ, CENPR, and CENPU) were significantly higher in HCC than in normal tissues, and their mRNA levels were associated with the tumor stages (

Identifiants

DOI: 10.1155/2021/9971799 PMID: 34457090 PMC: PMC8387183
pubmed: 34457090
doi: 10.1155/2021/9971799
pmc: PMC8387183
doi:

Substances chimiques

Biomarkers, Tumor 0
CENPL protein, human 0
Cell Cycle Proteins 0
Chromosomal Proteins, Non-Histone 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9971799

Informations de copyright

Copyright © 2021 Zhongyuan Cui et al.

Déclaration de conflit d'intérêts

All authors have declared that they have no competing interests and have confirmed its accuracy.

Références

Oncol Lett. 2015 Nov;10(5):2699-2704
pubmed: 26722229
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Bioengineered. 2020 Dec;11(1):729-742
pubmed: 32635817
Mol Med Rep. 2018 Mar;17(3):4720-4728
pubmed: 29328419
Biomed Pharmacother. 2020 Mar;123:109795
pubmed: 31881483
Oncol Rep. 2017 Aug;38(2):735-744
pubmed: 28677729
Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87
pubmed: 19546858
Oncol Rep. 2013 Nov;30(5):2238-44
pubmed: 23970101
Cancer Manag Res. 2018 Dec 14;10:6971-6984
pubmed: 30588102
Oncol Rep. 2017 Jun;37(6):3484-3492
pubmed: 28498417
Int J Oncol. 2019 Jul;55(1):257-266
pubmed: 31115500
Oncol Lett. 2018 Nov;16(5):6721-6728
pubmed: 30405814
Mol Ther Oncolytics. 2018 Dec 18;12:103-111
pubmed: 30719500
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Onco Targets Ther. 2019 Jan 29;12:869-882
pubmed: 30774374
Hepatology. 2007 Apr;45(4):938-47
pubmed: 17393520
Am J Cancer Res. 2018 May 01;8(5):835-851
pubmed: 29888106
Biochem Biophys Res Commun. 2013 Jul 12;436(4):711-8
pubmed: 23791740
Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):124-8
pubmed: 18681325
Gene. 2018 Oct 20;674:80-86
pubmed: 29936263
Nat Commun. 2016 Aug 31;7:12619
pubmed: 27577169
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Nat Rev Mol Cell Biol. 2016 Jan;17(1):16-29
pubmed: 26601620
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Zhonghua Bing Li Xue Za Zhi. 2007 Mar;36(3):175-8
pubmed: 17535684
Mol Biol Cell. 2002 Jun;13(6):1929-39
pubmed: 12058060
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Histol Histopathol. 2007 Feb;22(2):191-7
pubmed: 17149692
PLoS One. 2019 Feb 4;14(2):e0207341
pubmed: 30716092
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Aging (Albany NY). 2018 May 11;10(5):973-987
pubmed: 29754146
Am J Chin Med. 2018;46(3):689-705
pubmed: 29595070
J Cancer. 2017 Jul 15;8(12):2163-2172
pubmed: 28819418
Oncotarget. 2017 May 25;8(43):73994-74005
pubmed: 29088763
PLoS One. 2011 Mar 15;6(3):e17794
pubmed: 21423629
Nat Rev Mol Cell Biol. 2015 Jul;16(7):443-9
pubmed: 25991376
PLoS One. 2012;7(8):e43223
pubmed: 22912832
J Exp Clin Cancer Res. 2019 Nov 8;38(1):458
pubmed: 31703591
Oncol Rep. 2012 Jan;27(1):168-73
pubmed: 21956590
Mol Ther. 2019 Jun 5;27(6):1153-1165
pubmed: 31010740
Nat Cell Biol. 2006 May;8(5):446-57
pubmed: 16622420
J Exp Clin Cancer Res. 2009 Dec 18;28:156
pubmed: 20021663
Biochim Biophys Acta. 2008 Sep;1786(1):32-40
pubmed: 18549824

Auteurs

Zhongyuan Cui (Z)

Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Dongfang Hospital, Xiamen University, Fuzhou, Fujian 350025, China.
ORCID: 0000-0001-9476-9870

Lijia Xiao (L)

Department of Disease Prevention and Control, General Hospital of Western Theater Command, Chengdu, Sichuan 610000, China.

Fengsui Chen (F)

Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Dongfang Hospital, Xiamen University, Fuzhou, Fujian 350025, China.
Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Fujian Medical University, Fuzhou, Fujian 350025, China.

Jielong Wang (J)

Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Dongfang Hospital, Xiamen University, Fuzhou, Fujian 350025, China.

Haiyan Lin (H)

Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Fujian Medical University, Fuzhou, Fujian 350025, China.

Dongliang Li (D)

Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Dongfang Hospital, Xiamen University, Fuzhou, Fujian 350025, China.
Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Fujian Medical University, Fuzhou, Fujian 350025, China.
ORCID: 0000-0001-5536-8468

Zhixian Wu (Z)

Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Dongfang Hospital, Xiamen University, Fuzhou, Fujian 350025, China.
Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force, Fujian Medical University, Fuzhou, Fujian 350025, China.
ORCID: 0000-0002-0708-6770

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › High mRNA Expression of
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › High mRNA Expression of
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › High mRNA Expression of
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cycle cellulaire › High mRNA Expression of
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines chromosomiques nonhistones › High mRNA Expression of
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › High mRNA Expression of
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de profil d'expression de gènes › High mRNA Expression of
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › High mRNA Expression of
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High mRNA Expression of
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › High mRNA Expression of
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › High mRNA Expression of
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › High mRNA Expression of
questionsmedicales.fr › Diagnostic › Pronostic › High mRNA Expression of
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › High mRNA Expression of
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › High mRNA Expression of
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › High mRNA Expression of